Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$191.51 - $216.16 $1.06 Million - $1.2 Million
5,536 Added 36.02%
20,906 $4.44 Million
Q2 2023

Aug 10, 2023

BUY
$187.64 - $206.25 $136,226 - $149,737
726 Added 4.96%
15,370 $2.96 Million
Q1 2023

May 11, 2023

SELL
$127.59 - $203.08 $160,635 - $255,677
-1,259 Reduced 7.92%
14,644 $2.96 Million
Q1 2022

May 12, 2022

BUY
$119.61 - $157.85 $87,793 - $115,861
734 Added 4.84%
15,903 $2.29 Million
Q4 2021

Feb 11, 2022

BUY
$142.57 - $190.86 $76,560 - $102,491
537 Added 3.67%
15,169 $2.35 Million
Q1 2021

May 14, 2021

BUY
$137.51 - $190.8 $280,382 - $389,041
2,039 Added 16.19%
14,632 $2.03 Million
Q4 2020

Feb 16, 2021

BUY
$164.63 - $211.93 $2.07 Million - $2.67 Million
12,593 New
12,593 $2.21 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.